s Sarepta Therapeutics worth $10 billion? Can you incarcerate a unicorn? And how many jobs can one man reasonably hold?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about the implications of Sarepta’s big week on Wall Street followed by an examination of the legal predicament (and romantic entanglements) of Theranos. Andreessen Horowitz venture capitalist Vijay Pande joins us to discuss how discerning biotech investors approach artificial intelligence, and then we talk about Atul Gawande’s work-life balance, the risks of biotech exuberance, and how to get rich on “right to try.”